Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808210 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00808210 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 28 participants.
The verdict
NCT00808210, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, active-controlled, double-blind, double-dummy, parallel-group, multicenter study in the United States enrolling patients with active RA. The study will enroll approximately 290 patients at approximately 130 sites.
Interventions
- DRUG Placebo
- DRUG Methylprednisolone
- DRUG Infliximab
- DRUG Methotrexate
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-03-05 |
| Est. Completion | 2012-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00808210
The ClinicalTrials.gov registry entry for NCT00808210 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00808210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00808210 about?
NCT00808210 is a clinical study titled "A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab". This is a Phase II, randomized, active-controlled, double-blind, double-dummy, parallel-group, multicenter study in the United States enrolling patients with active RA. The study will enroll approximately 290 patients at approximately 130 sites.
What is the current status of trial NCT00808210?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2009-03-05. Estimated completion is 2012-11-14.
What interventions are being tested in trial NCT00808210?
The interventions under investigation include: Placebo (DRUG), Methylprednisolone (DRUG), Infliximab (DRUG), Methotrexate (DRUG), Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT00808210?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.